Clinical Trial

Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma

Name: Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma — clinical trial record (NCT07414979)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The proposed study is a single arm Phase I trial aimed at treating up to 6 HLA-A\*0201+ and HLA-A\*24 02+ individuals with leptomeningeal disease from metastatic melanoma.

Trial Details

NCT Number	NCT07414979
Lead Sponsor	M.D. Anderson Cancer Center
Conditions	Leptomeningeal Melanoma
Enrollment	8 participants
Start Date	2026-08-31
Primary Completion	2028-03-22 (estimated)
Study Completion	2030-03-22 (estimated)
Updated on ClinicalTrials.gov	2026-08-12